醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

Archive > Volume 15 Issue 2 > 2023,15(2):169-180. DOI:https://doi.org/10.1016/j.chmed.2023.02.002 Prev Next

大黃蟄蟲丸的臨床抗腫瘤應(yīng)用及藥理機(jī)制研究

Reviews

Clinical antitumor application and pharmacological mechanisms of Dahuang Zhechong Pill

  • Article
  • Figures
  • Metrics
  • Preview PDF
  • Reference
  • Related
  • Cited by
  • Materials
    摘要:
    摘要：癌癥的發(fā)病率和死亡率仍然居高不下，這無疑影響了患病個體的生活質(zhì)量。盡管傳統(tǒng)療法的毒性仍然是一個明顯的挑戰(zhàn)，但在癌癥治療方面已經(jīng)取得了顯著的進(jìn)展。大黃蟄蟲丸由張仲景在《金匱要略》中研制而成，是一種有效的抗癌傳統(tǒng)中藥。在本綜述中，我們發(fā)現(xiàn)DHZCP在臨床上被用于治療肝癌、肺癌、胃癌、胰腺癌和其他癌癥。藥理學(xué)證據(jù)表明，其抗腫瘤機(jī)制主要涉及誘導(dǎo)細(xì)胞周期阻滯、細(xì)胞凋亡和自噬，以及抑制腫瘤細(xì)胞增殖、阻斷血管生成和轉(zhuǎn)移、增強(qiáng)免疫力和逆轉(zhuǎn)多藥耐藥性。本綜述為DHZCP的臨床應(yīng)用提供了堅(jiān)實(shí)的基礎(chǔ)，并可能促進(jìn)中醫(yī)藥的廣泛使用。

    Abstract:
    Cancer still has elevated morbidity and mortality, which undoubtedly impacts the life quality of affected individuals. Remarkable advances have been made in cancer therapy, although the toxicities of traditional therapies remain an obvious challenge. Dahuang Zhechong Pill (DHZCP), developed by Zhongjing Zhang in the Synopsis of the Golden Chamber, represents an effective anticancer traditional Chinese medicine (TCM). In this review, it was found that DHZCP is therapeutically utilized in liver, lung, gastric, pancreatic and other cancers in clinic. Pharmacological evidence showed that its anti-tumor mechanisms mainly involve induced cell cycle arrest, apoptosis and autophagy, as well as suppressed tumor cell proliferation, obstructed angiogenesis and metastasis, enhanced immunity, and reversal of multidrug resistance. The present review provides a solid basis for the clinical application of DHZCP and may promote the wide use of TCM in clinical antitumor application.

    關(guān)鍵詞:
    抗腫瘤作用;大黃蟄蟲丸;藥理機(jī)制;傳統(tǒng)中藥

    Keywords:


    Project Supported:
    This work was financially supported by National Science and Technology Major Projects (No. 2018ZX09201-011, 2018ZX09301-011-003), the National High Technology Research and Development Program of China (No. 2019YFC1711400).

    Clc Number:

WeChat

Mobile website